If you have trouble reading this newsletter, view the web version here

Why and how to supplement androgens in infertile women?
Thursday, January 16, 2020
7pm CET, 1pm ET
DHEA Survey
Across the global IVF community, there is a lack of consensus regarding the usage of DHEA to support patients both before, and during, treatment for egg collection. The survey below has been launched to learn from your clinical experience regarding this issue.
Take the DHEA Survey
About the webinar:
Informal survey data suggest that more than half of IVF centers worldwide in one form or the other supplement androgens to some of their female infertility patients. A majority do so in the form of dehydroepiandrosterone (DHEA) which is the substrate for testosterone (T) production in the human body. DHEA, itself an androgen with only minimal affinity to the androgen receptor, is clinically largely ineffective. Once converted to T, especially small growing follicles, however, greatly benefit from supplementation if women are hypo-androgenic. We here discuss the physiological underpinnings of androgen supplementation in selected infertile women and its practical application.

Norbert Gleicher, MD, FACOG, FACS
Medical Director and Chief Scientist, The Center for Human Reproduction – New York, President, The Foundation for Reproductive Medicine; Visiting Researcher Laboratory for Stem Cell and Molecular Embryology, The Rockefeller University, Prof. (Adj.), Department of Obstetrics and Gynecology, Vienna University School of Medicine, Vienna, Austria, Editor-in-Chief Emeritus, Journal of Assisted Reproduction and Genetics (JARG) and American Journal for Reproductive Immunology (AJRI), New York, N.Y., USA.

Click here to register for the webinar (January 16, 2020)
For questions please contact: contact@ivf-worldwide.com.

If you prefer not to receive future email communications from us, please unsubscribe here

This newsletter was sent using ITnewsletter